Teva Pharmaceutical Industries Limited [TEVA] Is Currently -10.48 below its 200 Period Moving Avg: What Does This Mean?

Teva Pharmaceutical Industries Limited [NYSE: TEVA] loss -10.48% or -0.97 points to close at $8.29 with a heavy trading volume of 35010732 shares. The company report on April 14, 2023 that Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2023 financial results on Wednesday, May 10, 2023 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.

It opened the trading session at $8.60, the shares rose to $8.69 and dropped to $8.10, the range by which the price of stock traded the whole day. The daily chart for TEVA points out that the company has recorded 2.73% gains over the past six months. However, it is still -22.27% lower than its most recent low trading price.

If we look at the average trading volume of 8.68M shares, TEVA reached to a volume of 35010732 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Teva Pharmaceutical Industries Limited [TEVA]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TEVA shares is $10.17 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TEVA stock is a recommendation set at 3.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Jefferies have made an estimate for Teva Pharmaceutical Industries Limited shares, keeping their opinion on the stock as Hold, with their previous recommendation back on January 19, 2023. While these analysts kept the previous recommendation, JP Morgan dropped their target price from $11 to $10. The new note on the price target was released on November 14, 2022, representing the official price target for Teva Pharmaceutical Industries Limited stock.

The Average True Range (ATR) for Teva Pharmaceutical Industries Limited is set at 0.31, with the Price to Sales ratio for TEVA stock in the period of the last 12 months amounting to 0.70. The Price to Book ratio for the last quarter was 1.17, with the Price to Cash per share for the same quarter was set at 2.22. Price to Free Cash Flow for TEVA in the course of the last twelve months was 10.04 with Quick ratio for the last quarter at 0.70.

Trading performance analysis for TEVA stock

Teva Pharmaceutical Industries Limited [TEVA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -10.57. With this latest performance, TEVA shares dropped by -4.38% in over the last four-week period, additionally plugging by 2.73% over the last 6 months – not to mention a drop of -18.33% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TEVA stock in for the last two-week period is set at 32.61, with the RSI for the last a single of trading hit 27.19, and the three-weeks RSI is set at 35.88 for Teva Pharmaceutical Industries Limited [TEVA]. The present Moving Average for the last 50 days of trading for this stock 9.48, while it was recorded at 9.16 for the last single week of trading, and 9.13 for the last 200 days.

Teva Pharmaceutical Industries Limited [TEVA]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Teva Pharmaceutical Industries Limited [TEVA] shares currently have an operating margin of +17.96 and a Gross Margin at +46.68. Teva Pharmaceutical Industries Limited’s Net Margin is presently recorded at -15.78.

Return on Total Capital for TEVA is now 8.36, given the latest momentum, and Return on Invested Capital for the company is -8.02. Return on Equity for this stock declined to -26.42, with Return on Assets sitting at -5.21. When it comes to the capital structure of this company, Teva Pharmaceutical Industries Limited [TEVA] has a Total Debt to Total Equity ratio set at 274.21. Additionally, TEVA Total Debt to Total Capital is recorded at 73.28, with Total Debt to Total Assets ending up at 49.21. Long-Term Debt to Equity for the company is recorded at 246.32, with the Long-Term Debt to Total Capital now at 65.83.

Reflecting on the efficiency of the workforce at the company, Teva Pharmaceutical Industries Limited [TEVA] managed to generate an average of -$214,683 per employee. Receivables Turnover for the company is 3.69 with a Total Asset Turnover recorded at a value of 0.33.Teva Pharmaceutical Industries Limited’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 1.10.

Teva Pharmaceutical Industries Limited [TEVA]: An earnings per share (EPS) analysis

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TEVA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Teva Pharmaceutical Industries Limited go to 3.60%.

An analysis of insider ownership at Teva Pharmaceutical Industries Limited [TEVA]

Positions in Teva Pharmaceutical Industries Limited stocks held by institutional investors increased at the end of Wednesday and at the time of the Wednesday reporting period, where 181 institutional holders increased their position in Teva Pharmaceutical Industries Limited [NYSE:TEVA] by around 47,076,058 shares. Additionally, 189 investors decreased positions by around 44,082,233 shares, while 109 investors held positions by with 471,536,287 shares. The mentioned changes placed institutional holdings at 562,694,578 shares, according to the latest SEC report filing. TEVA stock had 48 new institutional investments in for a total of 17,048,297 shares, while 50 institutional investors sold positions of 5,980,669 shares during the same period.


Please enter your comment!
Please enter your name here